About Medulla Pro

Incubated in Dec-2018 by Trendlines in collaboration with National Healthcare Group Singapore, Medulla Pro developed the technology and IP around real-time ultrasound guidance technology, with the patent granted in Singapore (2021) and China (2023).

Medulla Pro welcomed a new team in June 2024, to bring the technology to market as a viable product, aiming for a First-in-Human trial in Q2 2025.

Medulla Pro also embarked on the development of a second product in November 2024 - a single-operator nerve block device. This initiative, also in collaboration with NHG, represents Medulla Pro's commitment to driving innovation in needle insertion field. 

At Medulla Pro, we are proud to combine technology, clinical expertise, and close collaboration to bring clarity and confidence to needle insertion procedures. Together, we are shaping a future where healthcare providers can perform these critical interventions with greater ease and success.